|
1
|
No authors listed. Chemotherapy in
non-small cell lung cancer: a meta-analysis using updated data on
individual patients from 52 randomised clinical trials. Non-small
Cell Lung Cancer Collaborative Group. BMJ. 311:899–909. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Haura EB: Treatment of advanced
non-small-cell lung cancer: a review of current randomized clinical
trials and an examination of emerging therapies. Cancer Control.
8:326–336. 2001.PubMed/NCBI
|
|
3
|
Schiller JH: Current standards of care in
small-cell and non-small-cell lung cancer. Oncology. 61(Suppl 1):
3–13. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ohsaki Y, Tanno S, Fujita Y, et al:
Epidermal growth factor receptor expression correlates with poor
prognosis in non-small cell lung cancer patients with p53
overexpression. Oncol Rep. 7:603–607. 2000.PubMed/NCBI
|
|
5
|
Nicholson RI, Gee JM and Harper ME: EGFR
and cancer prognosis. Eur J Cancer. 37(Suppl 4): 9–15. 2001.
View Article : Google Scholar
|
|
6
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Paez JG, Janne PA, Lee JC, et al: EGFR
mutations in lung cancer: correlation with clinical response to
gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Han SW, Kim TY, Hwang PG, et al:
Predictive and prognostic impact of epidermal growth factor
receptor mutation in non-small-cell lung cancer patients treated
with gefitinib. J Clin Oncol. 23:2493–2501. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shigematsu H, Lin L, Takahashi T, et al:
Clinical and biological features associated with epidermal growth
factor receptor gene mutations in lung cancers. J Natl Cancer Inst.
97:339–346. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Carey KD, Garton AJ, Romero MS, et al:
Kinetic analysis of epidermal growth factor receptor somatic mutant
proteins shows increased sensitivity to the epidermal growth factor
receptor tyrosine kinase inhibitor, erlotinib. Cancer Res.
66:8163–8171. 2006. View Article : Google Scholar
|
|
11
|
Borras E, Jurado I, Hernan I, Gamundi MJ,
Dias M, Marti I, Mane B, Arcusa A, Agundez JA, Blanca M and
Carballo M: Clinical pharmacogenomic testing of KRAS, BRAF and EGFR
mutations by high resolution melting analysis and ultra-deep
pyrosequencing. BMC Cancer. 11:4062011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhou C, Wu YL, Chen G, et al: Erlotinib
versus chemotherapy as first-line treatment for patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase
3 study. Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fenton KN and Richardson JD: Diagnosis and
management of malignant pleural effusions. Am J Surg. 170:69–74.
1995. View Article : Google Scholar
|
|
14
|
Therasse P, Arbuck SG, Eisenhauer EA, et
al: New guidelines to evaluate the response to treatment in solid
tumors. European Organization for Research and Treatment of Cancer,
National Cancer Institute of the United States, National Cancer
Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000.
View Article : Google Scholar
|
|
15
|
Giaccone G, Herbst RS, Manegold C, et al:
Gefitinib in combination with gemcitabine and cisplatin in advanced
non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin
Oncol. 22:777–784. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Herbst RS, Giaccone G, Schiller JH, et al:
Gefitinib in combination with paclitaxel and carboplatin in
advanced non-small-cell lung cancer: a phase III trial - INTACT 2.
J Clin Oncol. 22:785–794. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jian G, Songwen Z, Ling Z, et al:
Prediction of epidermal growth factor receptor mutations in the
plasma/pleural effusion to efficacy of gefitinib treatment in
advanced non-small cell lung cancer. J Cancer Res Clin Oncol.
136:1341–1347. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bosari S, Marchetti A, Buttitta F, et al:
Detection of p53 mutations by single-strand conformation
polymorphisms (SSCP) gel electrophoresis. A comparative study of
radioactive and nonradioactive silver-stained SSCP analysis. Diagn
Mol Pathol. 4:249–255. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fan X, Furnari FB, Cavenee WK, et al:
Non-isotopic silver-stained SSCP is more sensitive than automated
direct sequencing for the detection of PTEN mutations in a mixture
of DNA extracted from normal and tumor cells. Int J Oncol.
18:1023–1026. 2001.PubMed/NCBI
|
|
20
|
Kimura H, Fujiwara Y, Sone T, et al: EGFR
mutation status in tumour-derived DNA from pleural effusion fluid
is a practical basis for predicting the response to gefitinib. Br J
Cancer. 95:1390–1395. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kimura H, Kasahara K, Kawaishi M, et al:
Detection of epidermal growth factor receptor mutations in serum as
a predictor of the response to gefitinib in patients with
non-small-cell lung cancer. Clin Cancer Res. 12:3915–3921. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kubo A, Koh Y, Kawaguchi T, et al:
Malignant pleural effusion from lung adenocarcinoma treated by
gefitinib. Intern Med. 50:745–748. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang X, Zhao Y, Wang M, et al: Detection
and comparison of epidermal growth factor receptor mutations in
cells and fluid of malignant pleural effusion in non-small cell
lung cancer. Lung Cancer. 60:175–182. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Han HS, Lim SN, An JY, et al: Detection of
EGFR mutation status in lung adenocarcinoma specimens with
different proportions of tumor cells using two methods of
differential sensitivity. J Thorac Oncol. 7:355–364. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tsai TH, Wu SG, Chang YL, et al: Effusion
immunocytochemistry as an alternative approach for the selection of
first-line targeted therapy in advanced lung adenocarcinoma. J
Thorac Oncol. 7:993–1000. 2012. View Article : Google Scholar : PubMed/NCBI
|
